For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $11.5 in the prior trading day, Roivant Sciences Ltd (NASDAQ: ROIV) closed at $11.39, down -0.96%. In other words, the price has decreased by -$0.96 from its previous closing price. On the day, 3.36 million shares were traded. ROIV stock price reached its highest trading level at $11.64 during the session, while it also had its lowest trading level at $11.37.
Ratios:
Our goal is to gain a better understanding of ROIV by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 33.47 and its Current Ratio is at 33.47. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On February 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $17.
On January 05, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $20.Piper Sandler initiated its Overweight rating on January 05, 2024, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 21 ’25 when Venker Eric sold 100,000 shares for $11.52 per share. The transaction valued at 1,152,000 led to the insider holds 1,462,223 shares of the business.
Venker Eric bought 100,000 shares of ROIV for $1,151,942 on Jul 21 ’25. On Jun 20 ’25, another insider, Venker Eric, who serves as the President & COO of the company, sold 100,000 shares for $11.45 each. As a result, the insider received 1,145,000 and left with 1,462,223 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ROIV now has a Market Capitalization of 7742990848 and an Enterprise Value of 3455863040. For the stock, the TTM Price-to-Sale (P/S) ratio is 101.63 while its Price-to-Book (P/B) ratio in mrq is 1.69. Its current Enterprise Value per Revenue stands at 118.95 whereas that against EBITDA is -3.222.
Stock Price History:
The Beta on a monthly basis for ROIV is 1.15, which has changed by 0.060521364 over the last 52 weeks, in comparison to a change of 0.17774606 over the same period for the S&P500. Over the past 52 weeks, ROIV has reached a high of $13.06, while it has fallen to a 52-week low of $8.73. The 50-Day Moving Average of the stock is 1.84%, while the 200-Day Moving Average is calculated to be 1.90%.
Shares Statistics:
The stock has traded on average 6.23M shares per day over the past 3-months and 4924200 shares per day over the last 10 days, according to various share statistics. A total of 695.94M shares are outstanding, with a floating share count of 401.31M. Insiders hold about 40.97% of the company’s shares, while institutions hold 65.73% stake in the company. Shares short for ROIV as of 1751241600 were 41098083 with a Short Ratio of 6.60, compared to 1748563200 on 44430557. Therefore, it implies a Short% of Shares Outstanding of 41098083 and a Short% of Float of 8.25.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Current recommendations for the stock of the company come from 3.0 analysts. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.2 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$0.81 and -$1.22 for the fiscal current year, implying an average EPS of -$1.01. EPS for the following year is -$1.25, with 4.0 analysts recommending between -$1.06 and -$1.4.
Revenue Estimates
6 analysts predict $7.23M in revenue for the current quarter. It ranges from a high estimate of $15M to a low estimate of $1.78M. As of the current estimate, Roivant Sciences Ltd’s year-ago sales were $55.13MFor the next quarter, 6 analysts are estimating revenue of $7.32M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $1.78M.
A total of 7 analysts have provided revenue estimates for ROIV’s current fiscal year. The highest revenue estimate was $60M, while the lowest revenue estimate was $7.12M, resulting in an average revenue estimate of $29.42M. In the same quarter a year ago, actual revenue was $29.05MBased on 6 analysts’ estimates, the company’s revenue will be $43.54M in the next fiscal year. The high estimate is $112M and the low estimate is $20M.
